Incretin-based therapies with GLP-1 Receptor Agonists (RAs) and Dipeptidyl Peptidase-4 (DPP-4) inhibitors improve insulin secretion and/or peripheral insulin sensitivity in patients with T2DM [30,31,32]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.